Comparative Pharmacology
Head-to-head clinical analysis: MEPERGAN versus ULTRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPERGAN versus ULTRAM.
MEPERGAN vs ULTRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meperidine is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system, mimicking endogenous endorphins to produce analgesia. Promethazine is a phenothiazine antipsychotic that antagonizes histamine H1, dopamine D2, muscarinic acetylcholine, and alpha-adrenergic receptors, providing sedation and antiemetic effects.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Meperidine 50-100 mg and promethazine 25-50 mg IM/IV every 3-4 hours as needed. Maximum meperidine dose: 600 mg/day.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day (for extended-release: 100 mg once daily, titrated up to 300 mg once daily).
None Documented
None Documented
Meperidine: 3-4 hours (terminal; increased in hepatic impairment). Promethazine: 9-16 hours (terminal; prolonged in elderly).
Tramadol: ~6 hours; M1 metabolite (O-desmethyltramadol): ~7 hours; prolonged in renal/hepatic impairment
Renal elimination of metabolites (meperidine: ~90% as metabolites, <5% unchanged; promethazine: ~70-80% as metabolites, <1% unchanged). Biliary/fecal excretion is minimal (<10% for both).
Renal: ~90% (tramadol and metabolites; conjugated metabolites are major), Fecal: ~10%
Category C
Category C
Opioid Analgesic/Antiemetic Combination
Opioid Analgesic